(3b,6a,12b,24R)-20,24-Epoxy-3,12,25-trihydroxydammaran-6-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside

Pseudoginsenoside F₁₁ is an ocotillol-type ginsenoside that has been found in P. ginseng and has diverse biological activities. In vivo, pseudoginsenoside F₁₁ (10 mg/kg) prevents tubular cell apoptosis, decreases in renal glutathione peroxidase (GPX) and superoxide dismutase (SOD) levels, and increases in renal lipid peroxide levels in a rat model of nephrotoxicity induced by cisplatin . It reduces infarct size, brain water content, and cortical accumulation of autophagosomes in a rat model of ischemic stroke induced by permanent middle cerebral artery occlusion. Pseudoginsenoside F₁₁ (4 and 8 mg/kg) inhibits morphine-induced memory impairment in the Morris water maze and development of morphine-induced conditioned place preference in mice. It also reduces hippocampal advanced glycation end product (AGE) and malondialdehyde (MDA) levels, increases hippocampal SOD activity and glutathione (GSH) levels, and attenuates cognitive impairment in the Morris water maze in a mouse model of D-galactose-induced mild cognitive impairment.

White solid

Pseudoginsenoside F11 is an oxotillol-type ginsenoside which displayes neuroprotective activity.

[1] HONGBO WANG. The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo.[J]. Scientific Reports, 2014: 4986. DOI: 10.1038/srep04986
[2] YUE-YANG LIU. Pseudoginsenoside-F11 attenuates cerebral ischemic injury by alleviating autophagic/lysosomal defects[J]. CNS Neuroscience & Therapeutics, 2017, 23 7: 567-579. DOI: 10.1111/cns.12702
[3] ZHU LI . Antagonistic Effect of Pseudoginsenoside-F11 on the Behavioral Actions of Morphine in Mice[J]. Pharmacology Biochemistry and Behavior, 2000, 66 3: Pages 595-601. DOI: 10.1016/s0091-3057(00)00260-4
[4] ZHEN ZHANG. Pseudoginsenoside-F11 attenuates cognitive impairment by ameliorating oxidative stress and neuroinflammation in dgalactose-treated mice[J]. International immunopharmacology, 2019, 67: Pages 78-86. DOI: 10.1016/j.intimp.2018.11.026